Ayman M. Noreddin, Ph.D. Associate Professor Department of Pharmacy Practice and Pharmaceutical Sciences Director Duluth Center for Clinical and Translational Research (DCCTR) Graduate Faculty Department of Experimental and Clinical Pharmacology Integrated Biological Sciences Program University of Manitoba, Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine Office: 115 Life Science, Duluth Telephone Number(s): 218-726-6028 Office 218-726-6041 Lab E-mail Address: noreddin@umn.edu

Education:

American College of Clinical Pharmacy Research Fellowship (Infectious Diseases)
Pharmacokinetics/Pharmacodynamics Research Fellowship, Faculty of Medicine, University of Manitoba
Visiting Scholar (Molecular Biology and Cancer Research), Department of Medicine, Stanford University
Ph.D., Pharmaceutical Sciences (Clinical Pharmacy), University of the Pacific
M.Sc., Pharmaceutical Sciences (Biochemistry), Cairo University
B.Sc., Pharmaceutical Sciences, Cairo University

Research Focus:

My research group has focus in the area of anti-infective translational research in relation to antimicrobial resistance. Our goal is to improve patient care by maximizing clinical outcomes and preventing the development of bacterial resistance. The approach taken by my research team is defined by both bench investigations as well as clinical simulation studies:

• In-Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) modeling of infection
  Cutting edge in-vitro pharmacodynamic modeling techniques (for both planktonic as well as biofilm growing cells) are utilized to mimic concentration-time profile and populations encountered in human patients. Our goal is to design strategies that optimize anti-infective efficacy and prevent the selection of drug resistant mutants during anti-infective therapy.
  

• Mathematical modeling and clinical simulation analysis
  This translational approach involves integration of pre-clinical pharmacokinetic/pharmacodynamic data and early clinical pharmacokinetics data into mathematical modeling and Monte Carlo simulation routines. Our goal is to elucidate exposure-response relationship for target identification and optimal design of clinical trials.

Laboratory

Selected Publications:

Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Palatnik LP, Johnson J, Noreddin A, Harding GK, Nicolle LE, Hoban DJ; NAUTICA Group. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2005;26(5):380-8.

Noreddin AM, Haynes VL and Zhanel GG. Pharmacokinetics and Pharmacodynamics of the new quinolones. Journal of Pharmacy Practice 2005;18(6):1-12.

Noreddin AM, Hoban DJ and Zhanel GG. Comparison of Gatifloxacin and Levofloxacin administered at various dosing regimens to hospitalized patients with community acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents 2005;26(2):120-5.

Zhanel GG, Johnson C, Noreddin A, Gin A, Vercaigne L, Hoban DJ. Ertapenem: review of a new carbapenems. Expert Rev Anti Infect Ther 2005;3(1):23-39.

Noreddin A, Marras TK, Sanders K, Chan CK,  Hoban DJ and Zhanel GG. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using Levofloxacin 500 mg, 750mg and 1000mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents 2004;24(5):479-484.

Zhanel GG, Johnson C, Hisanaga T, MendozaC, Laing N, Noreddin A, Wierzbowski A, Hoban DJ. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J Antimicrob Chemother 2004;54(6):1072-7.

Smith HJ, Noreddin AM, Siemens CG, Schurek KN, Greisman J, Hoban DJ and Zhanel GG. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae using genetics instead of pharmacokinetics/pharmacodynamics. Antimicrobial Agents Chemother 2004;48(9):3630-5.

Schroth R, Hitchon C, Zacharias J, Uhanovaj J, Noreddin A, Tabacks P and Moffatt. Hepatitis B vaccination for patients with chronic renal failure. Cochrane Database Syst Rev. 3:CD003775, 2004.

Book Chapters:

Zhanel GG and Noreddin AM. Pharmacokinetics and pharmacodynamics of the new generation quinolones. In: Recent advances in antimicrobial agents and chemotherapy. Global Reviews; 2004.

Zhanel G and Noreddin A. Pharmacokinetics and pharmacodynamics (PK/PD) of fluoroquinolones: tools for combating bacteria and preventing resistance. In: The quinolones: an unfolding story. Birkhauser, Verlag AG, Basel, Switzerland; 2003. (Biosciences (Milestones in Drug Therapy).

PubMed